Envoys Meet with Putin Inside Trump’s High-Stakes Push for Russia Deal

Envoys Meet with Putin: Inside Trump’s High-Stakes Push for Russia Deal

A pivotal shift in the geopolitical landscape occurred yesterday as White House envoys Jared Kushner and Steve Witkoff traveled to Moscow to meet with Putin. This high-level engagement marks a critical juncture in the Russia-Ukraine war, moving beyond preliminary discussions to direct negotiations on a controversial U.S.-backed peace framework. For the government contracting base, this…

Did the US Commit Any War Crimes

Did the US Commit Any War Crimes?

A Shockwave in Washington On December 2, 2025, Washington was shaken by revelations surrounding a U.S. military strike on a suspected drug-trafficking vessel in the Caribbean. What began as a mission to intercept narcotics spiraled into a legal and political firestorm when reports confirmed that a second strike targeted survivors clinging to the wreckage. The…

A Complete Guide to Post-Award Performance That Drives CPARS Success and Future Wins

A Complete Guide to Post-Award Performance That Drives CPARS Success and Future Winsv

Introduction: Winning Isn’t the Finish Line—It’s the Starting Line You’ve just won your first federal contract. Cue the confetti and happy dances! But hold on—winning a contract isn’t the end of the story. In government contracting, your post-award performance determines whether that contract becomes a one-off win or a springboard for years of growth. Agencies…

The Complete GovCon Market Entry Blueprint

The Complete GovCon Market Entry Blueprint

Welcome to the Wild (and Lucrative) World of Federal Contracting If you’re a new vendor trying to break into federal contracting, you’ve probably already Googled “How do I sell to the government?” and then immediately wished you hadn’t. Don’t worry—GovCon market entry may be intimidating, but it’s also one of the most predictable and opportunity-rich…

Novo Nordisks GLP1 Trial Falls Short

Novo Nordisk’s GLP‑1 Trial Falls Short

The Promise That Didn’t Deliver Novo Nordisk, the Danish pharmaceutical giant behind blockbuster drugs like Ozempic and Wegovy, has confirmed that its late‑stage trial of an older oral version of semaglutide failed to meet its main goal. The trial aimed to test whether the drug could slow cognitive decline in patients with Alzheimer’s disease. The…